147 related articles for article (PubMed ID: 33309417)
21. Detection of circulating tumour cells may add value in endometrial cancer management.
Ni T; Sun X; Shan B; Wang J; Liu Y; Gu SL; Wang YD
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():1-4. PubMed ID: 27756035
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach.
Lupe K; Kwon J; D'Souza D; Gawlik C; Stitt L; Whiston F; Nascu P; Wong E; Carey MS
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):110-6. PubMed ID: 17084542
[TBL] [Abstract][Full Text] [Related]
23. Development of an immune gene prognostic classifier for survival prediction and respond to immunocheckpoint inhibitor therapy/chemotherapy in endometrial cancer.
Liu J; Chen X; Jiang Y; Cheng W
Int Immunopharmacol; 2020 Sep; 86():106735. PubMed ID: 32619957
[TBL] [Abstract][Full Text] [Related]
24. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.
Kiess AP; Damast S; Makker V; Kollmeier MA; Gardner GJ; Aghajanian C; Abu-Rustum NR; Barakat RR; Alektiar KM
Gynecol Oncol; 2012 Nov; 127(2):321-5. PubMed ID: 22850412
[TBL] [Abstract][Full Text] [Related]
25. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial.
Wortman BG; Bosse T; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld H; van den Berg H; Slot A; De Winter KAJ; Verhoeven-Adema KW; Smit VTHBM; Creutzberg CL;
Gynecol Oncol; 2018 Oct; 151(1):69-75. PubMed ID: 30078506
[TBL] [Abstract][Full Text] [Related]
26. Accelerating precision anti-cancer therapy by time-lapse and label-free 3D tumor slice culture platform.
Xing F; Liu YC; Huang S; Lyu X; Su SM; Chan UI; Wu PC; Yan Y; Ai N; Li J; Zhao M; Rajendran BK; Liu J; Shao F; Sun H; Choi TK; Zhu W; Luo G; Liu S; Xu L; Chan KL; Zhao Q; Miao K; Luo KQ; Ge W; Xu X; Wang G; Liu TM; Deng CX
Theranostics; 2021; 11(19):9415-9430. PubMed ID: 34646378
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.
Young MR; Higgins SA; Ratner E; Yu JB; Mani S; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Damast S
Int J Gynecol Cancer; 2015 Mar; 25(3):431-9. PubMed ID: 25621409
[TBL] [Abstract][Full Text] [Related]
28. Evaluating and comparing immunostaining and computational methods for spatial profiling of drug response in patient-derived explants.
Miles GJ; Powley I; Mohammed S; Howells L; Pringle JH; Hammonds T; MacFarlane M; Pritchard C
Lab Invest; 2021 Mar; 101(3):396-407. PubMed ID: 33318618
[TBL] [Abstract][Full Text] [Related]
29. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Färkkilä A; Gulhan DC; Casado J; Jacobson CA; Nguyen H; Kochupurakkal B; Maliga Z; Yapp C; Chen YA; Schapiro D; Zhou Y; Graham JR; Dezube BJ; Munster P; Santagata S; Garcia E; Rodig S; Lako A; Chowdhury D; Shapiro GI; Matulonis UA; Park PJ; Hautaniemi S; Sorger PK; Swisher EM; D'Andrea AD; Konstantinopoulos PA
Nat Commun; 2020 Mar; 11(1):1459. PubMed ID: 32193378
[TBL] [Abstract][Full Text] [Related]
30. Cytotoxic T Cells Are Replaced by Novel Clones After Immune Checkpoint Blocker Therapy.
Xie P; Lefraçnois P; Litvinov IV
J Cutan Med Surg; 2020; 24(3):314-315. PubMed ID: 32421426
[No Abstract] [Full Text] [Related]
31. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues.
Tamura H; Higa A; Hoshi H; Hiyama G; Takahashi N; Ryufuku M; Morisawa G; Yanagisawa Y; Ito E; Imai JI; Dobashi Y; Katahira K; Soeda S; Watanabe T; Fujimori K; Watanabe S; Takagi M
Oncol Rep; 2018 Aug; 40(2):635-646. PubMed ID: 29917168
[TBL] [Abstract][Full Text] [Related]
32. Revolutionizing the landscape of colorectal cancer treatment: The potential role of immune checkpoint inhibitors.
Tolba MF
Int J Cancer; 2020 Dec; 147(11):2996-3006. PubMed ID: 32415713
[TBL] [Abstract][Full Text] [Related]
33. Current treatment options for endometrial cancer.
Santin AD; Bellone S; O'Brien TJ; Pecorelli S; Cannon MJ; Roman JJ
Expert Rev Anticancer Ther; 2004 Aug; 4(4):679-89. PubMed ID: 15270671
[TBL] [Abstract][Full Text] [Related]
34. Use of patient-derived explants as a preclinical model for precision medicine in colorectal cancer: A scoping review.
Mui M; Clark M; Vu TMSH; Clemons N; Hollande F; Roth S; Ramsay R; Michael M; Heriot AG; Kong JCH
Langenbecks Arch Surg; 2023 Oct; 408(1):392. PubMed ID: 37816905
[TBL] [Abstract][Full Text] [Related]
35. Novel ex vivo ovarian cancer tissue explant assay for prediction of chemosensitivity and response to novel therapeutics.
Ricciardelli C; Lokman NA; Sabit I; Gunasegaran K; Bonner WM; Pyragius CE; Macpherson AM; Oehler MK
Cancer Lett; 2018 May; 421():51-58. PubMed ID: 29425684
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis.
Rodrigues da Cunha Colombo Bonadio R; Gondim Meira Velame Azevedo R; Harada G; Cabral Severino da Costa S; Costa Miranda V; de Freitas D; Abdo Filho E; Alves de Oliveira Ferreira P; Gabrielli F; Del Pilar Estevez Diz M
J Glob Oncol; 2018 Sep; 4():1-8. PubMed ID: 30241227
[TBL] [Abstract][Full Text] [Related]
37. Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model.
Frederick PJ; Kendrick JE; Straughn JM; Della Manna DL; Oliver PG; Lin HY; Grizzle WE; Stockard CR; Alvarez RD; Zhou T; LoBuglio AF; Buchsbaum DJ
Int J Gynecol Cancer; 2009 Jul; 19(5):814-9. PubMed ID: 19574765
[TBL] [Abstract][Full Text] [Related]
38. Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers.
Kharma B; Baba T; Mandai M; Matsumura N; Murphy SK; Kang HS; Yamanoi K; Hamanishi J; Yamaguchi K; Yoshioka Y; Konishi I
Int J Cancer; 2013 Nov; 133(9):2234-44. PubMed ID: 23595697
[TBL] [Abstract][Full Text] [Related]
39. Endometrial cancer: Molecular markers and management of advanced stage disease.
Arend RC; Jones BA; Martinez A; Goodfellow P
Gynecol Oncol; 2018 Sep; 150(3):569-580. PubMed ID: 29843906
[TBL] [Abstract][Full Text] [Related]
40. High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.
Reyes HD; Miecznikowski J; Gonzalez-Bosquet J; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Stephan JM; Hanjani P; Guntupalli S; Tewari KS; Backes F; Ramirez N; Fleming GF; Filiaci V; Birrer MJ; Leslie KK
Gynecol Oncol; 2017 Aug; 146(2):247-253. PubMed ID: 28532857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
